Healthcare stocks were lower late Monday afternoon with the NYSE Healthcare Index down 0.3% and the State Street Healthcare Select Sector SPDR ETF (XLV) declining 0.4%.
The iShares Biotechnology ETF (IBB) was fractionally lower.
In corporate news, Zoetis (ZTS) shares fell 7.5% after BNP Paribas lowered the company's price target to $146 from $185, following the company's Q1 results late last week.
Energy stocks were higher late Monday afternoon, with the NYSE Energy Sector Index and the State Street Energy Select Sector SPDR ETF (XLE) each rising 2.4%.The Philadelphia Oil Service Sector Index was adding 1.8%, and the Dow Jones US Utilities Index rose 1%.Front-month West Texas Intermediate crude oil rose 2.6% to $97.93 a barrel, and the global benchmark Brent crude contract was advancing 2.8% to $104.16 a barrel. Henry Hub natural gas futures gained 6% to $2.92 per 1 million BTU.In corporate news, Enbridge (ENB) is well-positioned to benefit from global energy security trends and rising demand for energy infrastructure, which are creating expanded opportunities across its businesses, RBC Capital Markets said in a note. Enbridge shares rose 1.7%.BP (BP) has a "second chance" to deleverage and restore financial health, supported by higher commodity prices that could put it on firmer footing in coming years, RBC Capital Markets said in a note. RBC upgraded BP to outperform from sector perform, while maintaining its 700 pence ($9.52) price target. BP shares rose 2.1%.Halliburton (HAL) and Blackstone (BX) will invest a combined $1 billion into energy startup VoltaGrid in a deal that values the firm at over $10 billion, Bloomberg reported. Halliburton shares added 1%.National Energy Services Reunited (NESR) shares jumped past 9% after it reported higher Q1 adjusted earnings and revenue.
Financial stocks fell Monday with the NYSE Financial Index declining 0.4% and the State Street Financial Select Sector SPDR ETF (XLF) easing 0.1%.The Philadelphia Housing Index shed 1.2%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) rose 0.4%.Bitcoin (BTC-USD) added 0.7% to $81,990, and the yield for 10-year US Treasuries rose 4.6 basis points to 4.41%.In economic news, the pace of US existing home sales increased 0.2% to a 4.02 million seasonally adjusted annual rate in April from 4.01 million in March, below the expectations for a 4.05 million rate in a survey compiled by Bloomberg, data from the National Association of Realtors showed.In corporate news, Brookfield Asset Management (BAM) plans to invest $500 million in OpenAI Deployment Co. Brookfield shares fell 1.7%.Blackstone's (BX) real estate debt arm, Blackstone Real Estate Debt Strategies, launched a lending platform to provide capital and flexibility to US homebuilders, aiming to support construction of over 50,000 for-sale homes annually. Blackstone shares declined 1.9%.Apollo Global Management (APO) said its managed funds agreed to buy Emerald Holding (EEX) and Questex to form a combined business events platform. Separately, Apollo is in discussions with potential buyers to sell its MidCap Financial Investment (MFIC) business development company, the Wall Street Journal reported. Apollo values the business at about $3 billion, the report said. Apollo shares fell 2.1%, and MidCap Financial Investment dropped 5.2%.
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Healthcare Select Sector SPDR ETF (XLV) declining 0.4%.The iShares Biotechnology ETF (IBB) was little changed.In corporate news, Zoetis (ZTS) shares fell 7.5% after BNP Paribas cut its price target to $146 from $185, following the company's Q1 results late last week.Moderna (MRNA) has been working on early-stage vaccines targeting hantaviruses, Bloomberg reported Friday, citing a company statement. The research began before recent infections were reported aboard the Dutch-flagged Hondius, the report said. Moderna shares fell 3.7%.Sonida Senior Living (SNDA) shares fell 3.3% after the company reported Q1 loss of $2.39 per diluted share, widening from the loss of $0.77 a year earlier. Analysts polled by FactSet expected a loss of $1.53.Erasca (ERAS) entered into a clinical trial collaboration and supply agreement with Merck (MRK) to study its investigational drug ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumors. Erasca shares rose 3%.